Can Organoid Model Reveal a Key Role of Extracellular Vesicles in Tumors? A Comprehensive Review of the Literature
Yang Zhang,Anqing Lu,Zixuan Zhuang,Su Zhang,Sicheng Liu,Haining Chen,Xuyang Yang,Ziqiang Wang
DOI: https://doi.org/10.2147/ijn.s424737
IF: 7.033
2023-09-28
International Journal of Nanomedicine
Abstract:Yang Zhang, 1, 2, &ast Anqing Lu, 2– 4, &ast Zixuan Zhuang, 1, 2 Su Zhang, 5 Sicheng Liu, 5 Haining Chen, 1, 2 Xuyang Yang, 1, 2 Ziqiang Wang 1, 2 1 Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China; 2 Department of General Surgery, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China; 3 Department of Central Transportation, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China; 4 West China School of Nursing, Sichuan University, Chengdu, 610041, People's Republic of China; 5 Research Laboratory of Tumor Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-Related Molecular Network and National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ziqiang Wang; Xuyang Yang, Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China, Email ; Extracellular vesicles (EVs) are small membrane-bound vesicles that are released by cells into the extracellular environment. The role of EVs in tumors has been extensively studied, and they have been shown to play a crucial role in tumor growth, progression, and metastasis. Past research has mainly used 2D-cultured cell line models to investigate the role of EVs in tumors, which poorly simulate the tumor microenvironment. Organoid technology has gradually matured in recent years. Organoids are similar in composition and behavior to physiological cells and have the potential to recapitulate the architecture and function of the original tissue. It has been widely used in organogenesis, drug screening, gene editing, precision medicine and other fields. The integration of EVs and organoids has the potential to revolutionize the field of cancer research and represents a promising avenue for advancing our understanding of cancer biology and the development of novel therapeutic strategies. Here, we aimed to present a comprehensive overview of studies using organoids to study EVs in tumors. Keywords: organoids, extracellular vesicles, tumors, model, review Extracellular vesicles (EVs) are small membrane-bound vesicles that are released by cells into the extracellular environment. 1 They contain a variety of bioactive molecules, including proteins, lipids, and nucleic acids, and are involved in intercellular communication and the regulation of various physiological and pathological processes. 2 EVs are a group of nanovesicles that can be mainly divided into 3 categories based on their cellular origin: exosomes, microvesicles and apoptotic bodies. 3 It is difficult to distinguish them using common isolation methods (differential ultracentrifugation, density gradient centrifugation, size exclusion chromatography, filtration, polymer-based precipitation, immunological separation, etc.) due to the lack of specific markers and the fact that the sizes or diameters of these EV subtypes partially overlap. The minimal information for studies of extracellular vesicles 2018 (MISEV2018) guideline noted that EVs were more appropriate than other terms, such as exosomes or microvesicles. 4 Therefore, we use the term EVs to unify the nomenclature throughout this review. The role of EVs in tumors has been extensively studied, and they have been shown to play a crucial role in tumor growth, progression, and metastasis. 5,6 Tumor-derived EVs can transfer oncogenic cargo to neighboring or distant cells, leading to the alteration of the tumor microenvironment and the promotion of cancer cell survival and proliferation. In addition, tumor cells generally secrete more EVs than their counterparts. 7 For instance, colorectal cancer (CRC)-derived EVs can promote distant metastasis. Mechanistically, miR-25-3p can be transferred from CRC cells to endothelial cells via EVs, which target KLF2 and KLF4, resulting in the induction of vascular permeability and angiogenesis. 8 Melanoma-derived exosomes can promote tumor growth and metastases. Mechanistically, melanoma-derived exosomes can reprogram bone marrow progenitors towards pro-vasculogenic and pro-metastatic phenotypes by transferring the receptor tyrosine kinase MET. 9 In the field of medical research, many drugs or inventions have produced promising results in laboratories but have failed in clinical trials. It was reported that the success rate o -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology